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OBJECTIVES The purpose of this study was to analyze the utility of patient-alert features in implantable
cardioverter defibrillators (ICDs).
BACKGROUND Various alert features producing acoustic warning signals have been implemented in newer
generation ICDs, but their role in early detection of system-related complications has not
been systematically evaluated.
METHODS In 240 patients implanted with Medtronic ICD devices, the following alert features were
routinely activated: pacing lead impedance 200 or 2,000 , high-voltage lead impedance
10 or 200 , low battery voltage (elective replacement indicator), long charge time
(18 s), 3 shocks delivered per episode, and all therapies in a zone delivered. Alert events
occurring during follow-up were assessed in relation to actual findings (hospital charts, chest
X-rays, ICD printouts including sensing/pacing/defibrillation threshold tests, episode data)
to determine incidence, sensitivity, and specificity of the alert function.
RESULTS During 12.2  8.9 months, 24 alert events occurred in the 240 patients (pacing lead
impedance, n  4; high-voltage lead impedance, n  7; low battery voltage, n  1; 3
shocks, n  6; all therapies, n  6). A total of 22 serious complications (necessitating
reprogramming or device/lead replacement) were observed, 14 of which were primarily
identified through a patient alert (lead fracture, n  11; connector defect, n  1; T-wave
oversensing, n  1; battery depletion, n  1). This reflects a sensitivity of 64% and a
specificity of 96% of the alert function for serious complications. With 14 of 24 patient alerts
being caused by serious complications, the positive predictive value reached 58%.
CONCLUSIONS Patient-alert features are a useful additional tool facilitating early detection of serious ICD
complications, but they do not substitute for regular ICD follow-up, because of their low
sensitivity. (J Am Coll Cardiol 2004;44:95–8) © 2004 by the American College of
Cardiology Foundationa
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eystem-related complications still occur in a significant
roportion of patients with implantable cardioverter defi-
rillators (ICD). The majority of complications are lead-
elated and occur within three months after device implan-
ation (1–11); however, even during long-term follow-up,
ystem-related complications are encountered (1,3,12–16).
eeping in mind that many of these complications are
otentially life-threatening, immediate detection would be
esirable to ensure maximal safety. Therefore, Patient Alert
Medtronic Inc., Minneapolis, Minnesota) has been devel-
ped, which is a programmable feature that enables a
atient to be audibly alerted once one of various parameters
xceeds the normal range. The present study was designed
o assess the utility of this feature based on an analysis of
ncidence, cause, and clinical consequences of alert events.
ETHODS
tudy population. All patients implanted with respective
CD systems (Medtronic 7227, 7229, 7230, 7231, 7271,
272, 7273, 7275) between February 1999 and July 2002
From the University of Heidelberg/Cardiology, Heidelberg, Germany.
Manuscript received November 10, 2003; revised manuscript received February 3,e004, accepted March 16, 2004.nd followed up for at least three months postoperatively
ere included in this retrospective study.
tandard patient-alert settings. The following alert fea-
ures were routinely activated before hospital discharge:
) Pacing lead impedance 200 or 2,000 
) High-voltage lead (HVB) impedance 10 or 200 
) Low battery voltage (elective replacement indicator)
) Long charge time (18 s)
) 3 Shocks delivered in one episode
) All therapies in a zone delivered
ny abnormality in one of these parameters would audibly
lert the patient once daily at a programmable time. The
lert time was individually adapted to the patients’ waking
ours (usually 8 to 10 A.M.). All patients were instructed to
mmediately present to our ICD clinic if an alert signal
hould occur.
outine follow-up schedule. After ICD implantation, all
atients underwent a prehospital discharge test, including
easurement of standard lead parameters and induction of
entricular fibrillation (VF). Routine outpatient follow-up
as scheduled for one and three months postoperatively and
very three months thereafter. Chest X-rays were performed
very six months.
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Patient Alert in ICDs July 7, 2004:95–8ata acquired during routine three monthly follow-up
nd unplanned visits. The following data were acquired:
) Patient history
) Physical examination
) 12-lead electrocardiogram
) Device interrogation
) Episode data
) Battery voltage/charge time
) (P/)R-wave measurement
) Pacing threshold test
) Lead impedance test
) Oversensing tests, if suspected
ata evaluation. Data from routine follow-ups and un-
lanned visits (UPVs) prompted by patient-alert events
ere analyzed with respect to incidence, cause, and clinical
onsequences. A decrease in pacing impedance200  was
onsidered as an indicator of insulation failure, and a sudden
ncrease2,000 was categorized as a sign of lead fracture.
serious complication was defined as a device or lead
ysfunction necessitating surgical revision or immediate
eprogramming (e.g., lead fracture, exit block, undersensing,
versensing with inappropriate therapy, battery depletion).
ensitivity and specificity of the patient-alert function were
alculated for the detection of serious complications. Non-
erious complications disclosed through a patient alert were
onsidered as false positive alerts.
tatistics. Statistics were performed using SAS for Win-
ows Version 6.12 (SAS Institute, Cary, North Carolina).
or comparison between groups, a chi-square test was
pplied. A p value 0.05 was considered statistically
ignificant.
ESULTS
total of 240 patients were included and followed up for 12.2
8.9 months. The patients’ clinical characteristics are sum-
arized in Table 1. A total of 32 (13.3%) complications were
ncountered, of which 22 (9.2%) were judged to be serious
Table 2). During the follow-up period, 24 patients (10%)
xperienced an alert event: pacing lead impedance, n  4;
VB impedance, n  7; low battery voltage, n  1; 3
hocks, n  6; and all therapies, n  6. A total of 14 of 22
erious complications were primarily identified through Patient
lert (sensitivity 64%, specificity 96% [208 of 216]) (Table 2).
n the other hand, 14 of 24 alert events were caused by serious
omplications (positive predictive value 58%) (Tables 3 and 4).
Abbreviations and Acronyms
ICD  implantable cardioverter defibrillator
RV  right ventricle/ventricular
SVC  superior vena cava
UPV  unplanned visit
VF  ventricular fibrillationomplications identified through alert events or not associatedith alert events are specified in Table 2. Alert events were
ignificantly more common after device replacement (using
xisting leads) than after first implantation or complete system
device lead) reimplantation (9 of 37 24.3% vs. 15 of 203
7.4%, p  0.004). Furthermore, patients with abdominal
evices were more commonly affected by alert events (5
f 9 55.6% vs. 19 of 231 8.3%, p 0.001). Other clinical
arameters (ICD indication, underlying heart disease, age, and
o forth) did not differ between patients with and those without
lert events.
The lead fractures not associated with alert events (n 5)
ere detected as follows: massive oversensing with delivery
f all VF therapies prompting a UPV before the alert signal
ould occur (n  1); oversensing with 3 inappropriate
hocks either prompting UPVs (n  2) or diagnosed at
outine follow-up (n  2). In all cases (n  5), the sensing
ntegrity counter had collected 300 short RR intervals
120 to 130 ms) within three months.
Of note, five patients claimed to have perceived an alert
ignal, but upon device interrogation, no alert event was
ocumented. These “phantom” alerts were excluded from
tatistical analysis.
resentation of characteristic cases. CASE 1. Two months
fter routine follow-up in May 2003, a patient implanted
ith a single lead system (Medtronic 7229Cx device/6943
able 1. Clinical and Device-Related Characteristics of the
tudy Population
Parameters
ge (yrs) 62.5  12.3
eft ventricular ejection fraction (%) 41  15%
nderlying heart disease
Coronary artery disease 167 (70%)
Dilated cardiomyopathy 46 (19%)
Others 8 (3%)
No structural heart disease 19 (8%)
ndication for ICD implantation
Primary prevention of SCD 48 (20%)
Secondary prevention of SCD 192 (80%)
evice characteristics
Pectoral 231 (96%)
Abdominal 9 (4%)
First ICD implantation or system (device  lead)
reimplantation
203 (85%)
Device replacement 37 (15%)
CD  implantable cardioverter defibrillator; SCD  sudden cardiac death.
able 2. Serious Complications Classified According to the
ode of Detection
Type of Complication
Mode of Detection
Patient Alert Other
ead fracture 11 5
onnector defect 1 0
-wave oversensing 1 0
attery depletion 1 0
ensing defect 0 2
xit block 0 1
otal 14 8
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July 7, 2004:95–8 Patient Alert in ICDsead) due to ventricular tachycardia experienced an alert
vent triggered by a pacing lead impedance 2,000 .
uring ICD testing, normal sensing and pacing parameters
ere observed (pacing threshold 2 V/0.2 ms; R wave 7 mV);
o oversensing was documented, despite rigorous myopo-
ential testing. However, the pacing lead impedance alter-
ated between 410 to 440 and2,000. During surgical
evision, an incomplete lead fracture necessitating lead
eplacement was found. Without a patient-alert feature, this
omplication might have been missed even during consec-
tive follow-up visits, because single impedance measure-
ents as performed during routine check-up could have
ielded normal results.
ASE 2. Two weeks after routine follow-up in April 2002, a
atient implanted with an abdominal system in 1995 due to
esuscitated VF perceived an alert signal. The initial device
Medtronic 7218D) had been replaced with a Medtronic
227D in August 2000 due to battery depletion, leaving
oth leads in place (right ventricular [RV] apex, Medtronic
936; superior vena cava [SVC], Medtronic 6937). Device
nterrogation disclosed that the alert had been triggered by
high voltage lead impedance 200 . During myopoten-
ial testing, marked oversensing was documented in the far
eld electrogram derived between SVC and RV high
oltage lead (HVA/HVB). This suggested a conductor wire
reach of either the RV or the SVC high voltage lead.
lthough the chest X-ray was unsuspicious, surgical lead
evision was performed. Selective intraoperative impedance
easurements (unipolar) on both high voltage leads yielded
n RV lead impedance 200 , confirming lead fracture.
able 4. Alert Events Caused by Non-Serious Complications (n
Alert Events n Cause
3 Shocks in VT/VF zone 4 Inappropriate Rx (atrial fibrillatio
Appropriate Rx (VT termination
n  2)
ll therapies in VT/VF zone 4 Inappropriate Rx (atrial fibrillatio
n  1)
Inefficient ATP therapy in slow
VB impedance 10  1 Single measurement 10  (oth
oversensing test negative; X-ra
VF induction: proper device fu
VB impedance 200  1 D-connector in abdominal system
VF induction: proper device fu
able 3. Alert Events Caused by Serious Complications (n  14
Alert Event n
acing lead impedance 2,000  5 Lea
VB impedance 200  3 Lea
VB impedance 10  2 Lea
ll therapies in VT/VF zone 2 Lea
T-w
3 shocks delivered in VT/VF zone 1 Con
RI 1 Bat
RI  elective replacement indicator; HVB  high-voltage lead; VF  ventricularTP  antitachycardia pacing; HVB  high-voltage lead; VF  ventricular fibrillation; VISCUSSION
o the best of our knowledge, this is the first study to
valuate Patient Alert as an ICD feature designed to
acilitate early detection of system-related complications.
uring a mean follow-up of one year, 10% of the patients
xperienced an alert event. The majority of alert events were
aused by serious complications necessitating reprogram-
ing or device/lead replacement. As expected, most com-
lications detected through alert events were lead-related
86%). However, eight of 22 (36%) serious complications
ccurring during the follow-up period were not associated
ith alert events. According to our data, Patient Alert
ontributes to the early detection of system-related compli-
ations, but it does not substitute for regular follow-up
isits, because of its relatively low sensitivity (64%).
The incidence of ICD-related complications encountered
n clinical studies depends on factors such as cohort size,
ollow-up duration, definition of complications, device/lead
election, mode of implantation, and so forth. In fact,
ublished overall complication rates range from 3.9% to
3%, with lead-related complications varying between 2.1%
nd 22%. With 13.3% (32 of 240) overall and 7.9% (20 of
40) lead-related complications, the present study was
omparable with other mid-term follow-up trials in newer
eneration ICDs (2,4,5).
Based on the parameters monitored, the alert feature
olds the potential for detection of lead- and device-related
omplications such as lead fracture, dislodgment, insulation
efect, and sudden battery depletion. However, in the
bsence of automatic sensing/pacing threshold tests, sensing
) (False Positives)
Therapy
 2) Reprogramming  pharmacologic (n  2)
iring 4 shocks; VF induction confirming proper device function
(n  2)
2; atrial flutter, Reprogramming (n  1), RF ablation (n  2)
one (ATP only) Reprogramming
e 11–16 );
suspicious;
n
None
tal ion oxidation?);
n
None
ue Positives)
Cause Therapy
ture Lead replacement
ture Lead replacement
ture Lead replacement
ture with oversensing (n  1) Lead replacement (n  1)
versensing (n  1) Reprogramming
r defect with oversensing Device replacement
epletion Device replacement
tion; VT  ventricular tachycardia. 10
n; n
requ
n n 
VT z
erwis
y: un
nctio
(me
nctio) (Tr
d frac
d frac
d frac
d frac
ave o
necto
tery dT  ventricular tachycardia.
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Patient Alert in ICDs July 7, 2004:95–8nd pacing defects with preserved lead continuity are
issed. Therefore, in its present form, the feature’s sensi-
ivity in diagnosing system-related complications is neces-
arily limited. Nevertheless, the prompt detection of serious
omplications in a considerable proportion of patients, as
emonstrated in this study, clearly justifies its routine use.
ccording to our data, the integration of sensing integrity
ounters ( short interval counters) might enhance the
ensitivity of the alert feature.
eprint requests and correspondence: Dr. Ruediger Becker,
niversity of Heidelberg/Cardiology, Bergheimer Strasse 58,
9115 Heidelberg, Germany. E-mail: ruediger_becker@med.uni-
eidelberg.de.
EFERENCES
1. Ellenbogen KA, Wood MA, Shepard RK, et al. Detection and
management of an implantable cardioverter defibrillator lead failure.
J Am Coll Cardiol 2003;41:73–80.
2. Grimm W, Menz V, Hoffmann J, et al. Complications of third-
generation implantable cardioverter defibrillator therapy. Pacing Clin
Electrophysiol 1999;22:206–11.
3. Mehta D, Nayak HM, Singson M, et al. Late complications in
patients with pectoral defibrillator implants with transvenous defibril-
lator lead systems: high incidence of insulation breakdown. Pacing
Clin Electrophysiol 1998;21:1893–900.
4. Rosenquist M, Beyer T, Block M, et al. Adverse events with
transvenous implantable cardioverter-defibrillators, a prospective mul-
ticenter study. Circulation 1998;98:663–70.
5. Schwacke H, Drogemuller A, Siemon G, et al. Komplikationen mit
Sonden bei 340 Patienten mit einem implantierbaren Kardioverter/
Defibrillator. Z Kardiol 1999;88:559–65.6. Babuty D, Fauchier JP, Charniot JC, et al. Mid-term complications of
automatic implantable cardiac defibrillators. Arch Mal Coeur Vaiss
2000;93:1269–75.
7. Degeratu FT, Khalighi K, Peters RW, et al. Sensing lead failure in
implantable defibrillators: a comparison of two commonly used leads.
J Cardiovasc Electrophysiol 2000;11:21–4.
8. Hoffmann E, Steinbeck G. Experience with pectoral versus abdominal
implantation of a small defibrillator: a multicenter comparison in 778
patients. Eur Heart J 1998;19:1085–98.
9. Kron J, Herre J, Renfroe EG, et al. Lead-and device-related compli-
cations in the antiarrhythmics versus implantable defibrillators trial.
Am Heart J 2001;41:92–8.
0. Sandstedt B, Kennergren C, Schaumann A, et al. Short-and long-term
performance of a tripolar down-sized single lead for implantable
cardioverter defibrillator treatment: a randomized prospective Euro-
pean multicenter study. Pacing Clin Electrophysiol 1998;21:2087–94.
1. Gold MR, Peters RW, Johnson JW, et al. Complications associated
with pectoral implantation of cardioverter defibrillators. Pacing Clin
Electrophysiol 1997;20:208–11.
2. Schulte B, Schwarz T, Sperzel J, et al. Dysfunctions of transvenous
cardioverter/defibrillator electrode systems: clinical significance of system
integrated diagnosis and measurement function—possibilities of partially
automated system control. Z Kardiol 1998;87:630–9.
3. Brady PA, Friedman PA, Trusty JM, et al. High failure rate for an
epicardial implantable cardioverter-defibrillator lead: implications for
long-term follow-up of patients with an implantable cardioverter-
defibrillator. J Am Coll Cardiol 1998;31:616–22.
4. Mattke S, Muller D, Markewitz A, et al. Failures of epicardial and
transvenous leads for implantable cardioverter defibrillators. Am
Heart J 1995;130:1040–4.
5. Lawton JS, Ellenbogen KA, Wood MA, et al. Sensing lead-related
complications in patients with transvenous implantable cardioverter-
defibrillators. Am J Cardiol 1996;78:647–51.
6. Nunain SO, Roelke M, Trouton T, et al. Limitations and late compli-
cations of third-generation automatic cardioverter-defibrillators. Circula-
tion 1995;91:2204–13.
